Abbonarsi

Optimizing routine screening for cardiac sarcoidosis through use of commonly available studies - 27/02/21

Doi : 10.1016/j.rmed.2021.106331 
Arthur W. Holtzclaw a, , Zorana Mrsic b, Tyler L. Church a, John N. Shumar c, Robert A. Liotta d, Saira N. Aslam e, Joseph R. Fontana f, Joel A. Nations a, Angeline Lazarus a, Robert F. Browning a, Aaron B. Holley a, John H. Sherner g, Sean A. McKay a
a Walter Reed National Military Medical Center, Pulmonary and Critical Care, USA 
b Womack Army Medical Center, Cardiology, USA 
c Walter Reed National Military Medical Center, Internal Medicine Residency, USA 
d Walter Reed National Military Medical Center, Radiology, USA 
e Walter Reed National Military Medical Center, Cardiology, USA 
f National Institute of Health/NHLBI, Pulmonary Branch, USA 
g Fort Belvoir Community Hospital, Pulmonary and Critical Care, USA 

Corresponding author. 8901 Rockville Pike, Bethesda, MD, 20889, USA.8901 Rockville PikeBethesdaMD20889USA

Abstract

Background

Sarcoidosis is a multisystem granulomatous disorder with unclear etiology. Morbidity and mortality vary based on organ involvement, with cardiac sarcoidosis (CS) associated with higher mortality; despite this, CS remains underdiagnosed. The Heart Rhythm Society (HRS) expert consensus statement recommends screening sarcoidosis patients for CS utilizing a symptom screen, EKG, and echocardiogram (TTE), while the American Thoracic Society (ATS) guideline recommends only EKG and symptom screening. These recommendations, however, are based on limited data with recommendations for further studies.

Research question

The purpose is to evaluate the prevalence of abnormal screening tests in patients with sarcoidosis and the correlation of these tests with the subsequent diagnosis of CS. A specific emphasis was placed on evaluating the sensitivity of the recommendations versus the sensitivity of a modified criteria.

Study design

and Methods: This study retrospectively evaluated a database of prospectively enrolled patients from a tertiary military academic center. All patients who underwent imaging with cardiac MRI and/or FDG-PET were identified. These results were correlated with screening studies (symptom screen, EKG, TTE, and ambulatory rhythm monitoring (ARM)) and used to calculate sensitivity, specificity, and positive and negative predictive values for each test. Using a clinical diagnosis of CS as the reference standard, the sensitivity and specificity of the HRS criteria were calculated and compared to a modified screening rubric developed a priori, consisting of minor changes to the criteria and the addition of ARM.

Results

This study evaluated 114 patients with sarcoidosis with 132 advanced imaging events, leading to a diagnosis of CS in 36 patients. Utilizing HRS screening recommendations, the sensitivity for CS was 63.9%, while the modified criteria increased sensitivity to 94.4%.

Interpretation

This study suggests that the HRS guidelines lack sensitivity to effectively screen for CS and that a modified screening model which includes ARM may be more effective.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Sarcoidosis, Cardiac sarcoidosis, Advanced imaging, Screening


Mappa


© 2021  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 178

Articolo 106331- marzo 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Transitions between COPD groups: A cross-sectional study in Turkey
  • P.A. Turan, O. Turan, F. Güldaval, C. Anar, G. Polat, M. Büyükşirin
| Articolo seguente Articolo seguente
  • Effect of patient immunodeficiencies on the diagnostic performance of serological assays to detect Aspergillus-specific antibodies in chronic pulmonary aspergillosis
  • Elizabeth Stucky Hunter, Bayu Wilopo, Malcolm D. Richardson, Chris Kosmidis, David W. Denning

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.